Pulse Biosciences (PLSE) Set to Release Earnings on Thursday

Pulse Biosciences (NASDAQ:PLSE) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.3095) per share and revenue of $0.52 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%. On average, analysts expect Pulse Biosciences to post ($1.34) EPS for the current fiscal year and ($1.41) EPS for the next fiscal year.

Pulse Biosciences Price Performance

NASDAQ:PLSE opened at $52.90 on Tuesday. Pulse Biosciences has a twelve month low of $12.56 and a twelve month high of $58.90. The company’s 50 day moving average is $51.13 and its two-hundred day moving average is $31.48.

Insider Buying and Selling

In other Pulse Biosciences news, COO Liane Teplitsky bought 1,001 shares of Pulse Biosciences stock in a transaction dated Tuesday, September 1st. The stock was acquired at an average cost of $49.95 per share, with a total value of $49,999.95. Following the purchase, the chief operating officer directly owned 4,095 shares in the company, valued at $204,545.25. This represents a 32.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders purchased 4,095 shares of company stock valued at $199,931 over the last quarter. 74.00% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on PLSE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, October 15th. Mizuho set a $55.00 price target on shares of Pulse Biosciences in a research report on Tuesday, October 13th. Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 6th. BTIG Research began coverage on shares of Pulse Biosciences in a research note on Wednesday, September 23rd. They set a “buy” rating and a $70.00 price objective for the company. Finally, Canaccord Genuity Group increased their price objective on shares of Pulse Biosciences from $43.00 to $58.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $60.20.

About Pulse Biosciences

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.